Immunotherapy studies in autologous cell therapies (ACT) present new and unique challenges involving the selection of appropriate sites with the experience and capabilities of running these complex studies. Qualified study sites and team members are essential to safeguard the integrity of the cell product. Following site identification and activation, it is necessary to continuously reevaluate obstacles that may interfere with blood procurement, product manufacture and delivery of treatment doses. Through the management of several recent ACT studies, Syneos Health™ has been able to identify issues that can impact site activation and subject enrollment and treatment.

Join for free to read